Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AP1189 can be dosed for three months in future clinical studies

SynAct Pharma AB ("SynAct") today announced that the company successfully has completed preclinical toxicology studies aimed to support 3 months dosing in future clinical trials with its lead candidate product, AP1189.No unforeseen observations were identified and importantly, the studies identified no-observed-adverse-effect levels (NOAEL) at the same or higher levels as identified in the four weeks preclinical toxicology studies conducted prior to initiation of the clinical development of the AP1189 compound. The preclinical studies have been conducted in accordance with international

Sinch completes the acquisition of MessageMedia

Stockholm, Sweden – November 5, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announces that the acquisition of MessageMedia has been completed. MessageMedia serves more than 60,000 customers and offers a web-based software-as-a-service (SaaS) suite that is purposefully tailored to meet the specific needs of small and medium-sized businesses. Sinch announced that it had entered into a definitive agreement to acquire the company on June 9, 2021. “With its easy-to-use software MessageMedia has demonstrated how businesses can use

Aker Horizons ASA: Private Placement successfully placed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Reference is made to the stock exchange announcement made by Aker Horizons ASA (the “Company”) on 4 November 2021 regarding the contemplated private placement (the “Private Placement”) in the Company. The Private Placement has been

Nordea Bank Abp: Repurchase of own shares on 04.11.2021

Nordea Bank AbpStock exchange release – Changes in company’s own shares04.11.2021 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 04.11.2021 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR*Code) **XSTO 381,947 10.85 4,144,878.26XHEL 363,110 10.86 3,944,355.00CEUX 218,231 10.85 2,368,326.67AQEU 40,291 10.86 437,397.

Stayble Therapeutics presents interim data from the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data and the results show continued good safety and tolerability and indicate good opportunities for a conclusive outcome of the study. Patient recruitment is still affected by the Covid-19 pandemic and the strict measures introduced in the study countries, primarily in Russia. The Board assesses that the slower patient recruitment means that study results can be presented in 2023.“We are very satisfied with our positive interim

Stabilisation notice

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.Carnegie Investment Bank (publ) (“Carnegie”) notifies that stabilisation measures have been undertaken in Storskogen Group AB’s (publ) (”Storskogen” or the “Company”) B-shares on Nasdaq Stockholm. As announced in connection with the offering and the admission to trading of the Company’s B-shares on Nasdaq Stockholm, Carnegie may act as stabilisation manager (the “Stabilisation Manager”)

Invitation to Tobii and Tobii Dynavox Capital Markets Day 2021

Tobii and Tobii Dynavox are pleased to invite analysts, investors, and media to its Capital Markets Day on November 30, 2021, at Helio GT30 in Stockholm, Sweden. Throughout the day, the management teams of both Tobii remainco and Tobii Dynavox will present their insights into both companies, their strategic directions, and financials. There will be opportunities to see demos and try some of our products. The Capital Markets Day will be a live streamed as well as a physical event with all necessary health and safety precautions considering the ongoing Coronavirus pandemic. The event

Tecnotree Corporation - Managers' Transactions - Subramanian

Person subject to the notification requirementName: Subramanian, RamaseshanPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20211103151522_2____________________________________________ Transaction date: 2021-11-01Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009010227Nature of the transaction: DISPOSAL Transaction details(1): Volume: 990 Unit price: 1.552 EUR(2): Volume: 557 Unit price: 1.552 EUR(3): Volume: 1,000 Unit price:

Remedy Entertainment Oyj: Managers' Transactions – Tero Virtala

Remedy Entertainment Oyj – Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Virtala, TeroPosition: Chief Executive OfficerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094021_4____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name:

Remedy Entertainment Oyj: Managers' Transactions – Terhi Kauppi

Remedy Entertainment Oyj – Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Kauppi, TerhiPosition: Chief Financial OfficerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094351_8____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name:

Remedy Entertainment Oyj: Managers' Transactions – Sami Järvi

Remedy Entertainment Oyj – Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Järvi, SamiPosition: Other senior managerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094003_6____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name: Remedy

Remedy Entertainment Oyj: Managers' Transactions – Mikaela Öberg-Mattila

Remedy Entertainment Oyj – Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Öberg-Mattila, MikaelaPosition: Other senior managerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094632_9____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument

Remedy Entertainment Oyj: Managers' Transactions – Johannes Paloheimo

Remedy Entertainment Oyj – Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Paloheimo, JohannesPosition: Other senior managerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094156_7____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name:

Remedy Entertainment Oyj: Managers' Transactions – Christopher Schmitz

Remedy Entertainment Oyj - Managers' Transactions 4 November 2021 at 6.45 p.m. (EET)____________________________________________ Person subject to the notification requirementName: Schmitz, ChristopherPosition: Other senior managerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATIONReference number: 7437003VZ3JPF7DBTG92_20211103094826_9____________________________________________ Transaction date: 2021-11-04Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name:

Oncopeptides focuses clinical development efforts to increase cash runway

STOCKHOLM — November 4, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the company has decided to reduce the activity level in the clinical development program with melflufen (INN melphalan flufenamide) to increase the company´s cash runway and at the same time support the ongoing marketing authorization application process in Europe. This will have implications on the following studies:· OCEAN study will continue with long-term follow-up and

Peptonic Medical intends to carry out a rights issue of approximately SEK 42 million and raises loan financing

Peptonic Medical AB (publ) ("PMED" or "the Company") announces today, November 4[th] , 2021, the intention to carry out a rights issue of units consisting of shares and warrants of series TO1 ("Unit") with preferential rights for the Company's existing shareholders (the "Rights Issue"). The proceeds from the Rights Issue and the warrants will mainly be used for the acquisition of Common Sense, for continued commercial launch and international expansion of the VagiVital and Lunettes product series as well as for the development of new products, including clinical studies. The Rights

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 04.11.2021

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 04.11.2021 at 18:30 EET ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 04.11.2021 Date 04.11.2021Exchange transaction BuyShare class ALEXAmount 400Average price/share 8.6150 EURHighest price/share 8.7000 EURLowest price/share 8.3600 EURTotal price 3,446.00 EUR The shares held by Alexandria Pankkiiriliike Oyj on 04.11.2021: ALEX 36,913 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 04.11.2021

United Bankers Corporation NOTIFICATION 04.11.2021 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 04.11.2021 Date 04.11.2021Exchange transaction BuyShare class UNITEDAmount 151Average price/share 13.8500 EURHighest price/share 13.8500 EURLowest price/share 13.8500 EURTotal price 2,091.35 EUR The shares held by United Bankers Corporation on 04.11.2021: UNITED 51,081 On behalf of United Bankers Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka

Terveystalo Plc: SHARE REPURCHASE 4.11.2021

Terveystalo Plc ANNOUNCEMENT  4.11.2021 Terveystalo Plc: SHARE REPURCHASE 4.11.2021 In the Helsinki Stock Exchange Trade date           4.11.2021Bourse trade         BuyShare                  TTALOAmount             18 000 SharesAverage price/ share    11,5428 EURTotal cost            207 770,40 EUR Terveystalo Plc now holds a total of 819 000 sharesincluding the shares repurchased on 4.11.2021 On behalf of Terveystalo Plc Nordea Bank Oyj Janne

Aker ASA: Key information relating to payment of cash dividend

Aker’s Board of Directors has, based on the authorization approved by the General Meeting on 28 April 2021, today decided to pay a cash dividend to Aker’s shareholders of NOK 11.75 per share. The dividend is based on the 2020 annual accounts.Dividend amount: NOK 11.75 per shareDeclared currency: NOKLast day including right: 5 November 2021Ex-date: 8 November 2021Record date: 9 November 2021Payment date: On or about 17 November 2021Approval date: 4 November 2021 -ENDS- For more information, please contact: Joachim Bjørni, Head of Investor Relations, Aker ASATel: +47

#21-365 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

GattyInstruments and Deversify receive Vinnova grant for study into the next generation of microsensors for breathalysers.

Vinnova, the Swedish Innovation Agency, has awarded GattyInstruments AB and Deversify AB a grant for a feasibility study into optimisation of breathalyser microsensors aimed at improving MEMS (Micro Electro-Mechanical System) size, speed and price. Photo: GattyInstruments“Vinnova has recognised the efforts of GattyInstruments and Deversify to improve human health through breath analysis. Understanding metabolic health is key to understanding human health overall. Deversify’s breathalyser Acetrack, with its global presence, is a pioneering product in this direction. This grant

Updated guidance 2021-2023 for OrderYOYO A/S

Company Announcement No. 12-2021 OrderYOYO A/SInside Information Copenhagen, November 4, 2021Updated guidance 2021 · Full year net revenue growth 2021 vs 2020 expected to be between 40-47% - to DKK 102.5–107.5m for full year 2021 · December 2021 ARR of DKK 110–125m corresponding to a growth of 6-20% vs. December 2020. Compared to latest guidance of DKK 125-135m · December 2021 GMV of DKK 1,100 – 1,400m compared to latest guidance of DKK 1,400 – 1,500m · Full year EBITDA of around DKK 0 compared to latest guidance of DKK 5-10m · Number of Restaurant Partners by end

There are no items matching the current filter
There are no more items matching the current filter
Back to top